

these are the 2 first cases of this mutation published in Galicia, in 2 members of the same family.

## References

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Critic Care Med.* 2003;168:818–900.
2. De Serres F, Blanco I. Role of alpha 1 antitrypsin in human health and disease. *J Int Med.* 2014;276:311–35.
3. Vidal R, Blanco I, Casas F, Jardí R, Miravittles M, Committee on the National Registry of individuals with alpha-1-antitrypsin deficiency. Guidelines for the diagnosis and management of alpha-1-antitrypsin deficiency. *Arch Bronconeumol.* 2006;42:645–59 [in Spanish].
4. Seixas S, Mendóça C, Costa F, Rocha J. Alpha1-antitrypsin null alleles: evidence for the recurrence of the L353FSX376 mutation and a novel G a transition in position +1 of intron 1C affecting normal mRNA splicing. *Clin Genet.* 2002;62:175–80.
5. Vidal R, Miravittles M, Jardí R, Torrella M, Rodríguez-Frías F, Moral P, et al. Study of the frequency of different phenotypes of alpha-1-antitrypsin in a population of Barcelona. *Med Clin (Barc).* 1996;107:211–4.
6. Hernández Pérez JM, Ramos Díaz R, Fumero García S, Pérez Pérez JA. Descripción de la deficiencia de alfa-1-antitripsina asociada al alelo PI\*Q0ourém en la isla de La Palma (España) y de un método de genotipado para su detección. *Arch Bronconeumol.* 2015;51:e1–3.
7. Blanco I, Lara B. Epidemiología del déficit de alpha-1 antitripsina. In: *Déficit de Alfa-1 antitripsin fisiopatología, enfermedades relacionadas diagnóstico y tratamiento.* 2nd ed. Barcelona: Editorial Respira, SEPAR; 2016.
8. Lara B, Martínez-Delgado B, Torres M, Marín-Arguedas S, Bustamante A, Miravittles M. Déficit de alfa-1-antitripsina asociada a la variante Mattawa. *Arch Bronconeumol.* 2013;49:548–50.

9. Vaz Rodrigues L, Costa F, Marques P, Mendonça C, Rocha J, Seixas S. Severe a-1 antitrypsin deficiency caused by Q0(Ourém) allele: clinical features, haplotype characterization and history. *Clin Genet.* 2012;81:462–9.

Ramón Antonio Tubío-Pérez,<sup>a,d,\*</sup> Milagros Blanco-Pérez,<sup>b</sup>  
Cristina Ramos-Hernández,<sup>a,c,d</sup> María Torres-Durán<sup>a,c,d</sup>

<sup>a</sup> Servicio de Neumología, Hospital Álvaro Cunqueiro, EOXI de Vigo, Vigo, Pontevedra, Spain

<sup>b</sup> Unidad de Citogenética y Genética Molecular, Servicio de Análisis Clínicos, EOXI de Vigo, Vigo, Pontevedra, Spain

<sup>c</sup> Grupo de Investigación Neumovigo I+i, Instituto de Investigación Biosanitaria Galicia Sur, Vigo, Pontevedra, Spain

<sup>d</sup> Centro galego Alfa-1-antitripsina, Galicia, Spain

\* Corresponding author.

E-mail address: [Ramon.Antonio.Tubio.Perez@sergas.es](mailto:Ramon.Antonio.Tubio.Perez@sergas.es)

(R.A. Tubío-Pérez).

Received 12 July 2017

Accepted 7 September 2017

1579-2129/

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Prognosis of Obesity Hypoventilation Syndrome With and Without Concomitant Obstructive Sleep Apnea Syndrome<sup>☆</sup>



### Pronóstico del síndrome de hipoventilación-obesidad con y sin síndrome de apnea obstructiva asociado

Dear Editor,

Obesity hypoventilation syndrome (OHS) is a clinical entity characterized by the coexistence of obesity and hypercapnia during waking hours. However, the lack of a universally accepted definition creates confusion, since no distinctions are made between patients with different grades of severity and forms associated, or not associated, with sleep apnea-hypopnea syndrome (SAHS).<sup>1–3</sup> Cabrera et al. proposed a severity stratification for OHS based on daytime PaO<sub>2</sub>, PaCO<sub>2</sub>, the apnea-hypopnea index (AHI), body mass index, and comorbidities, but this classification has not been associated with differences in prognosis. An earlier study published by our group in patients with a severe form of OHS, in which global respiratory failure was detected at diagnosis, found a 5-year mortality rate of 15.5%, and a 2-fold risk of death compared to patients with SAHS without diurnal hypoventilation.<sup>4</sup> Similarly to other studies,<sup>5–7</sup> the main cause of death was cardiovascular disease (CVD).

Masa et al. classified OHS patients in tertiles according to the number of desaturations of  $\geq 3\%$  per hour of recording (oxygen desaturation index, ODI). Although it differs from the AHI, the ODI should reflect the severity of the underlying SAHS, and a higher prevalence of CVD could be expected among patients with more

severe SAHS, but the authors found exactly the opposite.<sup>8</sup> They speculated that this may be because patients with more severe disease might seek medical intervention earlier, and so would receive earlier treatment for their cardiovascular risk factors. They also referred to a mechanism called “ischemic preconditioning”, in which repeated episodes of subclinical ischemia, triggered by nocturnal hypoxemia, may lead to angiogenic stimulation and the development of collateral circulation. Aside from this, the study shows that the stratification of OHS is associated with significant clinical consequences. However, no difference was made between patients with and without SAHS, who could constitute different phenotypes. Ojeda et al.,<sup>9</sup> in contrast, did distinguish between OHS with and without SAHS, and identified more OHS patients without SAHS (OHS-nonSAHS) than with SAHS (OHS-SAHS). This study found no differences in mortality between the 2 groups (about 28% at 5 years), but a trend toward improved survival in OHS-SAHS was identified. The study was criticized for not reporting cardiovascular comorbidities in both groups before and after treatment, since this might explain the improved (but non-significant) survival among the OHS-SAHS group.

Our group designed a retrospective chart review to compare the prognosis of OHS-SAHS and OHS-nonSAHS patients (approved by the Ethics Committee of Galicia: Reg. No. 2017/079). We reviewed the medical records of 124 patients diagnosed with OHS between 1995 and 2017 using restrictive criteria: global respiratory failure at time of diagnosis and pH  $\geq 7.34$ . Patient were matched 1:2 by date of diagnosis  $\pm 3$  years, sex, and an age range of  $\pm 10$  years. A total of 11 patients with OHS-nonSAHS (AHI < 5) and 22 with OHS-SAHS were finally included. At baseline, there were no significant differences between patients with OHS-nonSAHS and OHS-SAHS in mean age (67 vs 68.5 years;  $P=.88$ ), female sex (77.7% vs 77.1%;  $P=.1$ ), average body mass index (43 kg/m<sup>2</sup> vs 42.5 kg/m<sup>2</sup>;  $P=.81$ ), FVC (59.5% vs 49% predicted;  $P=.96$ ), baseline PaO<sub>2</sub> (51.5 $\pm$ 9.5 mmHg vs 48 $\pm$ 7.6 mmHg;  $P=.25$ ) and baseline PaCO<sub>2</sub> (54.7 $\pm$ 9.1 mmHg vs 60.6 $\pm$ 13.2 mmHg;  $P=.38$ ). Obviously, AHI was greater in OHS-SAHS patients with in OHS-nonSAHS

<sup>☆</sup> Please cite this article as: Rodríguez Alvarez A, Méndez Marote L, Castro Añón O, Golpe Gómez R, Pérez de Llano LA. Pronóstico del síndrome de hipoventilación-obesidad con y sin síndrome de apnea obstructiva asociado. *Arch Bronconeumol.* 2018;54:230–231.

**Table 1**  
Number of Deaths and Cardiovascular Events by Groups.

	OHS-nonSAHS (11)	OHS-SAHS (22)	P-value <sup>a</sup>
Death	1 (9.1)	9 (40.9)	.108
Cardiovascular events	4 (36.3)	10 (45.4)	.719

OHS: obesity hypoventilation syndrome; SAHS: sleep apnea-hypopnea syndrome. Data expressed in absolute frequencies and percentages.

<sup>a</sup> Values calculated with Fisher's exact test.

individuals (4 vs 30;  $P < .001$ ), as was the desaturation index  $\geq 4\%$  per hour of nighttime recording (14 vs 41;  $P < .001$ ). There were no differences in time with  $\text{SaO}_2 < 90\%$  (95.5% vs 89%;  $P = .162$ ). No significant differences were found in the prevalence of hypertension (72.7% in OHS-nonSAHS vs 95.4% in OHS-SAHS), diabetes (27.2% vs 36.3%), dyslipidemia (38.3% vs 50%), smoking (9.1% vs 13.6%), ischemic heart disease (9.1% vs 13.6%), heart failure (9.1% vs 22.7%), arrhythmias (0% vs 31.8%), cerebrovascular accidents (0% vs 4.55%) and atheromatosis (0% vs 4.5%) at the time of diagnosis, although there was a greater history of CVD in the OHS-SAHS group, which in a larger sample might have reached statistical significance. Mean follow-up was  $5.4 \pm 1.5$  years. All patients in the OHS-nonSAHS group received non-invasive mechanical ventilation (BiPAP, with additional oxygen in 7/11 cases), as did the majority of the OHS-SAHS patients (BiPAP initially in all, and after titration: BiPAP in 16/22, with additional oxygen in 15 and CPAP in 6 cases). There were no significant differences between OHS-nonSAHS and OHS-SAHS in the final determination of arterial blood gases:  $\text{PaO}_2$ :  $65 \pm 9.6$  mmHg vs and  $72 \pm 11.6$  mmHg, respectively ( $P = .10$ );  $\text{PaCO}_2$ :  $44.3 \pm 2.5$  mmHg vs  $43.2 \pm 3.3$  mmHg ( $P = .328$ ). No significant differences were observed in mortality and cardiovascular events during follow-up, but there was a clear trend toward a higher incidence of both in the OHS-SAHS group (Table 1). Causes of death were CVD (6 in OHS-SAHS), cancer (1 in OHS-nonSAHS and 2 in OHS-SAHS), and sepsis (1 in OHS-SAHS). The main limitations of this study are its retrospective nature and small sample size (although all large series reflect the difficulty of finding patients with OHS without SAHS, so 11 patients constitute a reasonable sample).<sup>4,10–12</sup> Given the trend observed in our results, a larger sample would perhaps have demonstrated significant differences in mortality and CVD events, which could be explained by greater cardiovascular comorbidities in OHS-SAHS: no patient died of respiratory failure. These results diverge clearly from those of Masa<sup>8</sup> and Ojeda,<sup>9</sup> although they make sense if we consider that SAHS on its own is associated with significant endothelial dysfunction, CVD, and a greater risk of risk of cardiovascular death.<sup>13–15</sup> OHS-SAHS and OHS-nonSAHS appear to be 2 different phenotypes of the disease, and only a multicenter prospective study, which may have to be international due to the above-mentioned difficulty in recruiting nonSAHS patients, will be able to identify differences in prognoses between the two.

## References

- Cabrera Lacalzada C, Diaz-Lobato S. Grading obesity hypoventilation syndrome severity. *Eur Respir J*. 2008;32:817–8.
- Rabec CA. Obesity hypoventilation syndrome. What's in a name? *Chest*. 2002;122:1498.
- Bandyopadhyay T. Obesity-hypoventilation syndrome, the name game continues. *Chest*. 2004;2004:352.
- Castro-Añón O, Pérez de Llano LA, de la Fuente Sánchez S, Golpe R, Méndez Marote L, Castro-Castro J, et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. *PLoS ONE*. 2015;10:e0117808. <http://dx.doi.org/10.1371/journal.pone.0117808>.
- Basoglu OK, Tasbakan MS. Comparison of clinical characteristics in patients with obesity hypoventilation syndrome and obese obstructive sleep apnea syndrome: a case-control study. *Clin Respir J*. 2014;8:167–74.
- Priou P, Hamel JF, Person C, Meslier N, Racineux JL, Urban T, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. *Chest*. 2010;138:84–90.
- Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. The use of health-care resources in obesity-hypoventilation syndrome. *Chest*. 2001;120:377–83.
- Masa JF, Corral J, Romero A, Caballero C, Terán-Santos J, Alonso-Álvarez ML, et al, on behalf of the Spanish Sleep Network. Protective cardiovascular effect of sleep apnea severity in obesity hypoventilation syndrome. *Chest*. 2016;150:68–79.
- Ojeda Castillejo E, de Lucas Ramos P, López Martín S, Resano Barrios P, Rodríguez Rodríguez P, Morán Caicedo L, et al. Noninvasive mechanical ventilation in patients with obesity hypoventilation syndrome, long-term outcome and prognostic factors. *Arch Bronconeumol*. 2015;51:61–8.
- Budweiser S, Riedl SG, Jörres RA, Heinemann F, Pfeifer M. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. *J Intern Med*. 2007;261:375–83.
- Pepin JL, Chouri-Pontarollo N, Orliaguet O, Lévy P. Alveolar hypoventilation during sleep and domiciliary assisted ventilation. *Rev Mal Respir*. 2005;22:113–25.
- Masa JF, Corral J, Alonso ML, Ordax E, Troncoso MF, Gonzalez M, et al. Spanish sleep network, efficacy of different treatment alternatives for obesity hypoventilation syndrome. Pickwick Study. *Am J Respir Crit Care Med*. 2015;192:86–95.
- Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. 2005;353:2034–41.
- Marin JM, Carrizo SJ, Vicente E, Agustí AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*. 2005;365:1046–53.
- Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA*. 2012;307:2161–8.

Ana Rodríguez Alvarez, Lidia Méndez Marote, Olalla Castro Añón, Rafael Golpe Gómez, Luis Alejandro Pérez de Llano\*

*Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain*

Corresponding author.

E-mail address: [eremos26@hotmail.com](mailto:eremos26@hotmail.com) (L.A. Pérez de Llano).

1579-2129/

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.